Selank

Περιγραφή

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia as an analog of the naturally occurring immunomodulatory peptide tuftsin, modified with a Pro-Gly-Pro C-terminal sequence for increased stability and bioavailability. It is primarily researched for its unique anxiolytic (anti-anxiety) and nootropic effects, acting through modulation of the GABAergic system, enkephalin degradation inhibition, BDNF (brain-derived neurotrophic factor) upregulation, and influence on serotonin, dopamine, and norepinephrine pathways—producing calming, mood-stabilizing, and cognitive-enhancing benefits without the sedation, dependence, tolerance, or withdrawal associated with traditional benzodiazepines or many other anxiolytics. Preclinical studies and limited human clinical trials (mostly conducted in Russia) have demonstrated Selank’s potential to significantly reduce symptoms of generalized anxiety disorder, neurasthenia, and adjustment disorders, improve attention, memory consolidation, learning capacity, and mental performance under stress, normalize emotional responses, and offer neuroprotective effects in models of brain injury or neurodegeneration. It is also explored for its immunomodulatory properties, including potential support for immune balance and anti-inflammatory actions in the central nervous system. In wellness, biohacking, and nootropic communities, Selank is commonly administered as a nasal spray (most popular route due to direct nose-to-brain delivery) at doses of 200–600 mcg (often 2–3 sprays per nostril) 1–3 times daily, or via subcutaneous injection at similar microgram ranges, with cycles typically lasting 10–30 days followed by breaks. Users frequently report rapid-onset calming effects (within 10–30 minutes nasally), reduced anticipatory anxiety, better stress resilience, improved focus during demanding tasks, enhanced mood stability, and clearer thinking without drowsiness or cognitive blunting. While generally well-tolerated with minimal reported side effects (occasional mild nasal irritation with spray form, rare transient fatigue or headache), Selank is not FDA-approved for any therapeutic, psychiatric, cognitive, or medical use as of 2026—it remains an investigational research peptide outside Russia and certain Eastern European countries where it has been used clinically under specific regulations. Human data is limited compared to Western pharmaceuticals, relying heavily on Russian studies, small trials, and widespread anecdotal evidence rather than large-scale international randomized controlled trials. It is not classified as a controlled substance in most jurisdictions but availability is restricted to research chemical suppliers or compounding pharmacies in some regions. Never use Selank without consulting a qualified healthcare provider knowledgeable in peptides or nootropics, as self-administration carries risks of improper dosing, contamination from unregulated sources, unexpected reactions, or interactions with other medications (e.g., SSRIs, anxiolytics). Prioritize evidence-based treatments for anxiety, stress, or cognitive concerns—consult a professional to assess suitability, and stay informed on evolving research or regulatory status. Selank is not a substitute for proven therapies, counseling, or lifestyle interventions.